Literature DB >> 9510449

Decreased trabecular bone mineral density in patients with phenylketonuria measured by peripheral quantitative computed tomography.

B Schwahn1, E Mokov, K Scheidhauer, B Lettgen, E Schönau.   

Abstract

The bone mineral density (BMD) of 14 children, adolescents, and adults with phenylketonuria (PKU) on dietary treatment (age 5-28 y; 6F, 8M) was investigated using peripheral quantitative computed tomography (pQCT) of the distal radius. BMD of total (TBMD) and spongy bone (SBMD) were compared to those of healthy gender-, age-, weight- and height-matched controls. We found a significant decrease of SBMD in patients with PKU while TBMD was only slightly decreased, reaching no statistical significance. These results indicate minor changes of BMD in patients with PKU under treatment, which are more accentuated in the trabecular bone compartment. One additional patient who was untreated until the pQCT investigation at the age of 10 y also showed markedly decreased SBMD and TBMD.

Entities:  

Mesh:

Year:  1998        PMID: 9510449     DOI: 10.1080/08035259850157886

Source DB:  PubMed          Journal:  Acta Paediatr        ISSN: 0803-5253            Impact factor:   2.299


  15 in total

1.  Elevated plasma phenylalanine concentrations may adversely affect bone status of phenylketonuric mice.

Authors:  S Yannicelli; D M Medeiros
Journal:  J Inherit Metab Dis       Date:  2002-09       Impact factor: 4.982

2.  Clinical therapeutics for phenylketonuria.

Authors:  Jaspreet Singh Kochhar; Sui Yung Chan; Pei Shi Ong; Lifeng Kang
Journal:  Drug Deliv Transl Res       Date:  2012-08       Impact factor: 4.617

3.  Analysis of the functional muscle-bone unit of the forearm in patients with phenylketonuria by peripheral quantitative computed tomography.

Authors:  Daniela Choukair; Carolin Kneppo; Reinhard Feneberg; Eckhard Schönau; Martin Lindner; Stefan Kölker; Georg F Hoffmann; Burkhard Tönshoff
Journal:  J Inherit Metab Dis       Date:  2016-11-22       Impact factor: 4.982

Review 4.  Nutritional issues in treating phenylketonuria.

Authors:  François Feillet; Carlo Agostoni
Journal:  J Inherit Metab Dis       Date:  2010-02-12       Impact factor: 4.982

5.  Cross-sectional study of bone metabolism with nutrition in adult classical phenylketonuric patients diagnosed by neonatal screening.

Authors:  Hironori Nagasaka; Hirokazu Tsukahara; Tomozumi Takatani; Yoshitami Sanayama; Masaki Takayanagi; Toshihiro Ohura; Osamu Sakamoto; Tetsuya Ito; Mika Wada; Makoto Yoshino; Akira Ohtake; Tohru Yorifuji; Satoshi Hirayama; Takashi Miida; Hiroki Fujimoto; Hiroshi Mochizuki; Toshikazu Hattori; Yoshiyuki Okano
Journal:  J Bone Miner Metab       Date:  2011-05-19       Impact factor: 2.626

6.  Increased spontaneous osteoclastogenesis from peripheral blood mononuclear cells in phenylketonuria.

Authors:  F Porta; I Roato; A Mussa; M Repici; E Gorassini; M Spada; R Ferracini
Journal:  J Inherit Metab Dis       Date:  2008-10-17       Impact factor: 4.982

Review 7.  Phenylketonuria: a review of current and future treatments.

Authors:  Naz Al Hafid; John Christodoulou
Journal:  Transl Pediatr       Date:  2015-10

Review 8.  Amino acid metabolism and autophagy in skeletal development and homeostasis.

Authors:  Akiko Suzuki; Junichi Iwata
Journal:  Bone       Date:  2021-02-10       Impact factor: 4.398

9.  Low bone strength is a manifestation of phenylketonuria in mice and is attenuated by a glycomacropeptide diet.

Authors:  Patrick Solverson; Sangita G Murali; Suzanne J Litscher; Robert D Blank; Denise M Ney
Journal:  PLoS One       Date:  2012-09-18       Impact factor: 3.240

10.  A Three-Year Longitudinal Study Comparing Bone Mass, Density, and Geometry Measured by DXA, pQCT, and Bone Turnover Markers in Children with PKU Taking L-Amino Acid or Glycomacropeptide Protein Substitutes.

Authors:  Anne Daly; Wolfgang Högler; Nicola Crabtree; Nick Shaw; Sharon Evans; Alex Pinto; Richard Jackson; Catherine Ashmore; Júlio C Rocha; Boyd J Strauss; Gisela Wilcox; William D Fraser; Jonathan C Y Tang; Anita MacDonald
Journal:  Nutrients       Date:  2021-06-17       Impact factor: 5.717

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.